Kallioniemi

Individualized Systems Medicine

Background

 

Research Strategy

Our new individualized systems medicine study is as part of a "grand challenge" programme at FIMM to improve cancer therapy. Using adult Acute Myeloid Leukaemia (AML) as a model disease, we aim to: (1) identify effective targeted drugs for AML patients by ex-vivo DSRT as well as genomic and molecular profiling, (2) understand how the molecular and functional features change during drug response and resistance based on paired samples, (3) create individual systems medicine models of AML driver signals and drug response/resistance, (4) translate these data towards individualized cancer treatment. The personalised medicine collaboration involves Wennerberg, Heckman/Knowles, Aittokallio and Lundin groups at FIMM and clinical collaborators at HUS.

In addition, the group is developing similar strategies in prostate cancer, where we work with established cancer cell lines, drug-resistant model systems, patient ex-vivo material and tumor tissues to profile drug response and resistance. We would like to identify the genes and signalling pathways that play a key role and could act as predictive biomarkers of drug response and resistance.

Last updated: 06.04.2016 - 12:55